Vergelijking
Retatrutide vs. Tirzepatide
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Metabool
Metabool
CAS-nr.
2381089-83-2
2023788-19-2
Molecuulmassa
4731.6 g/mol
4813 g/mol
Halfwaardetijd
144 h
116 h
Sequentie
Y-Aib-EGTFTSDYSIYLDKQAAQDFVQWLLDTGPSSGAPPPSYXEGTFTSDYSIYLDKIAQKAFVQWLIAGGPSSGAPPPSWerkingsmechanisme
Retatrutide
Retatrutide is a 39-amino-acid peptide with agonism at three incretin/energy-balance receptors: GLP-1R (insulin secretion, satiety), GIPR (insulin sensitivity, lipid metabolism) and the glucagon receptor (energy expenditure, lipolysis). The added glucagon activation is intended to raise catabolic energy expenditure while concurrent GLP-1/GIP action compensates the hyperglycaemic effect. Albumin binding via a fatty-acid side chain enables weekly dosing.
Tirzepatide
Tirzepatide is a 39-amino-acid peptide acting as a dual agonist at the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Activation of both incretin receptors via G-protein-coupled signalling raises insulin secretion in a glucose-dependent manner, lowers glucagon secretion and delays gastric emptying. Centrally, satiety perception is modulated. A fatty-acid side chain binds to serum albumin and extends the half-life to about five days.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
5
4
waarvan bij mensen
4
4
Geregistreerde effecten
4
4
Openstaande tegenstrijdigheden
1
1
Gedocumenteerde bijwerkingen
2
2
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Retatrutide and Tirzepatide?
- Retatrutide is classified as "Metabool", while Tirzepatide is classified as "Metabool". Retatrutide: Synthetic triagonist peptide that simultaneously activates the GLP-1, GIP and glucagon receptors. Developed by Eli Lilly; in phase-3 trials for obesity (TRIUMPH programme) and type 2 diabetes. No marketing approval yet. Tirzepatide: Synthetic peptide that simultaneously activates the GLP-1 and GIP receptor (dual agonist). Approved in the US and EU for type 2 diabetes (Mounjaro) and obesity (Zepbound). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Retatrutide or Tirzepatide?
- The highest available evidence level is "Humane RCT" for Retatrutide and "Humane RCT" for Tirzepatide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Retatrutide and Tirzepatide in Germany and the United States?
- Duitsland: Retatrutide — Niet goedgekeurd, Tirzepatide — Op recept. Verenigde Staten: Retatrutide — Niet goedgekeurd, Tirzepatide — Op recept. These are factual summaries with source and review date on the individual pages.